Table 3.

DNA Damage Response-Associated ncRNAs and Their Targets in Human Cancer

Name	Function	Target/interactor	Cancer phenotype	Cancer type	Refs.
let-7	TS	H-RAS, HMGA2	Induces apoptosis	Lung, breast	(198, 241)
miR-15/16	TS	Bcl-2, Wt-1	Induces apoptosis and decreases tumorigenicity	Chronic lymphocytic leukemia, pituitary adenoma	(17, 23, 41)
miR-155	OG	c-maf	Induces lymph proliferation	Chronic lymphocytic leukemia, lung, breast	(61, 92, 235)
miR-17∼92	OG	E2F1, Bim, PTEN	Co-operates with c-myc to induce lymphoma in mice, promotes lymph proliferative disorder, and enhances cell proliferation	Lymphoma, lung	(80, 145, 226)
miR-21	OG	PTEN, PDCD4, TPM1	Induces apoptosis and decreases tumorigenicity	Breast, cholangiocarcinoma, chronic lymphocytic leukemia, lung	(57, 146, 186, 252)
miR-221	OG	P27, p57	Promotes aggressive growth and cell proliferation	Hepatocellular carcinoma, glioblastoma	(38, 54, 66)
miR-29	TS	TCL-1, MCL1, DNMT3s	Induces apoptosis and decreases tumorigenicity	Non-small cell lung cancer, cholangiocarcinoma, lung	(151, 235)
miR-34	TS	E2F, CDK4, CDK6, cyclin E2	Induces apoptosis	Gastric, pancreatic, lung, neuroblastoma	(33, 95, 223)
miR-372/373	OG	LATS2	Promotes tumorigenesis in co-operation with RAS	Testicular tumors	(209)
ANRIL	OG	PRC1, PRC2	Suppresses senescence via INK4A	Prostate, leukemia	(108, 162, 238)
LincRNA-p21	TS	hnRNP-k	Mediates p53 signaling, induces apoptosis	Mouse models of lung, sarcoma, lymphoma	(88)